Cytek Biosciences
CTKB
155 hedge funds and large institutions have $361M invested in Cytek Biosciences in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 45 increasing their positions, 65 reducing their positions, and 38 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $372M → $361M (-$10.7M)
3.41% less ownership
Funds ownership: 66.53% → 63.12% (-3.4%)
6% less funds holding
Funds holding: 165 → 155 (-10)
24% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 38
31% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 65
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$13M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$7.93M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.17M |
| 4 |
Jane Street
New York
|
+$3.87M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$2.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$31.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.65M |
| 3 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$6.47M |
| 4 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
-$5M |
| 5 |
Morgan Stanley
New York
|
-$4.34M |
CTKB Hedge Fund Activity: Q2 2026 in Review
155 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q2 2026, worth a combined $361M — down 2.9% from $372M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of CTKB and 29 opened new positions — a net loss of 9 holders — while 65 trimmed existing stakes and 45 added.
The largest buyer was Millennium Management, adding an estimated $13M. The largest seller was BlackRock, cutting an estimated $31.7M.
- 155 institutional investors held Cytek Biosciences (CTKB) as of Q2 2026, down from 165 in Q1 2026.
- Funds reported $361M of Cytek Biosciences stock for Q2 2026, down 2.9% quarter-over-quarter.
- 29 funds opened new Cytek Biosciences positions in Q2 2026 and 38 closed out, a net change of -9 holders.
- The largest Cytek Biosciences buyer in Q2 2026 was Millennium Management, an estimated $13M added.
- The largest Cytek Biosciences seller in Q2 2026 was BlackRock, an estimated $31.7M sold.
Based on aggregated 13F filings for Q2 2026.